Long Covid-19UP-LONGCOVID-RNCT06928480
Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.
A study testing Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders and Treatment as Usual (TAU) in people with Long Covid-19 and Emotional Disorder, run by Instituto de Investigación Sanitaria Aragón at 2 sites in Spain.
Trial summary
This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Long Covid-19, Emotional Disorder, Anxiety
- What is being tested?
- Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders and Treatment as Usual (TAU)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 2 sitesSpain
- Study dates
- 1 May 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Residing in Autonomous Community of Aragon (Spain).
- Being at least 18 years old.
- Understanding of Spanish.
- Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection.
- Symptoms of depression (ODSIS≥7) and/or anxiety (OASIS≥8).
- Meeting the criteria for an emotional disorder diagnosis.
- Having access to Internet.
- Signing the informed consent.
Who cannot join
- Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection.
- Actually receiving psychological treatment.
- Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.).
- Active suicidal ideation at the time of the assessment.
- Individuals on psychotropic medication must maintain their dosage throughout the study, unless medically contraindicated.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain2 sites, 2 recruiting
- Not yet recruiting
Hospital Royo Villanova
Zaragoza, Zaragoza, 50015
Jorge Osma Jorge Osma, PhD, +34 978645390, osma@unizar.es
Verónica Martínez Borba Verónica Martínez Borba, PhD
- Recruiting
Hospital Royo Villanova
Zaragoza
Jorge J Osma, PhD, 978645390 ext. 861390, protocolounificadocovid19@gmail.com
About this study
This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain.
In this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, levels of chronic stress will be longitudinally evaluated in the experimental group through accumulated cortisol levels in hair, before and after the application of the UP.
Read the detailed description
The COVID-19 disease has caused one of the largest pandemics in history, with significant health, social, and economic negative consequences. A significant proportion of the population has not overcome these negative consequences. It has been found that 10-20% of patients with COVID-19 do not recover their previous health status and develop persistent symptoms over time. This condition has been defined by the WHO as post-COVID-19 condition or long COVID-19, characterized by the presence of physical, cognitive, and emotional symptoms that can last for months or even years after the acute COVID-19 infection. Some of the most prevalent symptoms are fatigue, difficulty breathing, and cognitive dysfunction, in addition to significant psychological impairments. Among these, emotional disorders (ED) are the most commonly reported in this population, including anxiety disorders, depressive disorders, and related conditions.
The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is a transdiagnostic Cognitive Behavioral Therapy-based pychological intervention, which has proven to be effective for the treatment of emotional disorders in different populations. The UP is focused on improving emotion regulation skills.
The main objective of this randomized controlled trial is to evaluate the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in 90 adults (45 in the control group and 45 in the experimental group) with long COVID and a comorbid emotional disorder. The researchers hypothesize that the application of the UP will result in a significant reduction in emotional symptoms in the experimental group, compared to the control group. To analyze this results, the evolution of symptoms (i.e., anxiety and depressive symptoms, etc.) will be assessed over time (before and after the intervention, as well as up to 12 months follow-up). Additionally, the acceptability and satisfaction of participants after receiving the UP will be analyzed, and it will be examined whether changes in emotional symptoms are associated with changes in long COVID physical symptoms. Changes in cortisol and cortisona levels will be longitudinally examined in the experimental group.
- Being tested
- Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, Treatment as Usual (TAU)
- Keywords
- Long COVID-19, Emotional Disorders, Emotion regulation skills, Unified Protocol, Transdiagnostic, Psychological, Cognitive Behavioral
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Anxiety Disorders, Emotional Regulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Unified Protocol for the Transdiagnostic Treatment of Emotional DisordersBehavioural
This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7).
In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows:
- Module 1 (session 1): Setting goals and maintaining motivation.
- Module 2 (sessions 2 and 3): Understanding your emotions.
- Module 3 (sessions 4 and 5): Mindful Emotions Awareness.
- Module 4 (sessions 6 and 7): Flexible thinking.
- Module 5 (session 8): Emotional baheviors.
- Module 6 (session 9): Facing physical sensations.
- Module 7 (sessions 10 and 11): Emotionl exposures.
- Module 8 (Session 12): Relapse prevention.
This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19.
After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition.
| Study group | Role | What they receive |
|---|---|---|
| Unified Protocol Psychological Intervention | Experimental | The 45 participants assigned to this condition will receive the Unified Protocol psychological intervention through 12 sessions. Weekly session will be conducted online (via Google Meet). Each sessions will last 2 hours. Receives: Behavioral: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders |
| Control Group-Waiting list | Other | The 45 participants assigned to this condition will remain as a control group on a waiting list for the 12 weeks of the program that participants in the experimental group receive. Receives: Other: Treatment as Usual (TAU) |
What is being measured
The primary outcome is the main question the study is designed to answer.
General Depression Severity and Interference Scale (ODSIS; Bentley et al., 2014. Validated in Spanish by Osma et al., 2019)
It assesses the frequency, intensity, severity and interference of depressive symptomatology through 5 items. total scores range from 0 to 20 points, higher scores indicating more severe depressive symptoms.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
General Severity and Interference Scale for Anxiety (OASIS; Norman et al., 2006. Validated in Spanish by Osma et al., 2019)
It consiste of 5 items that assess the frequency, intensity, severity and interference of anxious symptomatology. Total scores range from 0 to 20 points, higher scores represent more severe anxiety symptoms.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Secondary outcomes (12)
Memory Failures of Everyday, MFE (Sunderland et al., 1983; Montejo et al., 2014)
It assesses the frequency of forgetfulness and memory lapses in daily life. Errors include forgetting names, misplacing objects, difficulties in planning, or lapses in attention.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Multidimensional Inventory for Emotional Disorders (MEDI; Rosellini and Brown, 2019. Validated in Spanish by Osma et al., 2023)
It is composed by 49 items that evaluates the transdiagnostic profile of Emotional Disorders, which is composed of nine dimensions: neurotic temperament, positive temperament, depressed mood, somatic anxiety, arousal activation, social anxiety, intrusive cognitions, traumatic re-experiencing, and avoidance.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Emotional Regulation Difficulties Scale (DERS; Gratz and Roemer, 2004. Validated in Spanish by Hervás & Jódar, 2008)
Evaluation through 36 items of difficulties in emotional regulation by means of 5 subscales: lack of control, rejection, interference, inattention and emotional confusion. Higher scores indicate greater difficulties in emotion regulation.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
EuroQol (Brooks, 1996. Validated in Spanish by Badia et al., 1999)
It is composd by 5 items assessing self-perceived health status. Higher scores indicate better quality of life.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Distress Tolerance Scale (DTS; Sandín et al., 2017)
This scale evaluates, through 15 items, distress tolerance in the following dimensions: 1) Tolerance: perceived ability to tolerate emotional distress; 2) Appraisal: subjective assessment of distress; 3) Absortion: attention absorbed by negative emotions; 4) Regulation: strategies to alleviate distress.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Perceived Stress Scale (PSS; Remor y Carrobles, 2001)
This scale consists of 14 items designed to measure the level of perceived stress in daily life over the past month. The items are rated from 0 to 4, where 0 is "never" and 4 is "very often." Higher total scores indicate greater perceived stress.
Measured: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
An adaptation of Client Satisfaction Questionnaire (CSQ-8) of Larsen et al., 1979)
the adaptation made for this study includes 6 of the 8 items of the CSQ-8 (perceived quality, adequacy to previous expectations, recommendation of the treatment to friends or family, usefulness of the techniques learned, general satisfaction with the intervention and probability that they will choose an intervention of this type again) and one additional item related to the discomfort generated by the intervention. Likewise, a change has been made in the Likert response scale from 4 points in the original (0 = "Bad / Not at all" to 4 = "Excellent/Very Much") to 11 in the current one (0 = "Bad / Not at all to 10 = "Excellent/Very Much"). Higher scores represent greater satisfaction with the treatment.
Measured: After the treatment is applied (post-assessment; approximately 12 weeks after the intervention starts)
Evaluation questionnaire of the UP modules (Ad hoc)
This questionnaire has been elaborated ad hoc. It is composed of 7 questions; one general question that evaluates the usefulness of the program to improve emotional regulation and six specific questions that separately evaluate the usefulness of each of the techniques that are worked on in the different modules of the UP to better regulate emotions . The response scale ranges from 0 (not at all) to 10 (very much). Higher scores represent higher satisfaction with the treatment.
Measured: After the treatment is applied (post-assessment; approximately 12 weeks after the intervention starts)
Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005)
Brief neuropsychological test designed to assess mild cognitive impairment. It evaluates multiple cognitive domains, including visuospatial skills, memory, working memory, attention, concentration, language, executive functions, and orientation. It has a maximum score of 30 points, with a common cutoff score of 25 to identify potential cognitive deficits. A score of 25 or lower is considered indicative of cognitive impairment.
Measured: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Digit Symbol subtest-Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler, 1997)
This cognitive test presents a coding matrix in which the digits from 1 to 9 are paired with a symbol. On the same sheet, a series of digits is displayed with a blank space where participants must draw the corresponding symbol. The task must be completed as quickly as possible, with a 120-second limit to match the symbols with their respective numbers. If participants fail to complete the first four lines within the allotted time, they are given additional time to ensure they gain enough experience with the digit-symbol association. The tota score is based on the number of symbols correctly paired within 120 seconds (maximum score: 133). Immediately after completing the task, the researcher provides the participant with a new sheet containing the digits from 1 to 9 arranged in two lines. In this second part, participants must complete the blank spaces by drawing from memory the symbols corresponding to each number, with no time limit.
Measured: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Digit subtest from Wechsler Adult Intelligence Scale-IV (WAIS-IV; Wechsler, 2008)
The direct order digit task of this subtest evaluates verbal short-term memory and consists of a numeric recall task that measures the mechanical repetition of a sequence of numbers. The reverse order digit task assesses verbal working memory and requires participants to recall a sequence of numbers in reverse order (maximum score: 9). The memory capacity evaluated with these two tasks is defined as the longest sequence that participants can repeat without errors, allowing two attempts for each sequence length (maximum score: 8).
Measured: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Cortisol and cortisona levels
Hair sample will be collected from the posterior vertex or nape area, where growth is continuous and less exposed to contaminants. For this, a small portion of hair will be tied with thread near the cut area, which will allow identification of the portion closest to the scalp at the time of analysis and prevent hair loss. Using clean scissors, the hair will be cut as close as possible to the scalp, obtaining a segment of approximately 3 cm in length. This will allow for the evaluation of cortisol levels accumulated over the last three months, as hair grows on average 1 cm per month.
Measured: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2025
- Study start1 May 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Long Covid-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Instituto de Investigación Sanitaria Aragón
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Universitario Royo Villanova
- Responsible party
- Principal investigator, Jorge Javier Osma López, Universidad de Zaragoza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06928480
- Sponsor's protocol ID
- UP-LONGCOVID-RCT
- Other IDs
- PROY_S22_24
- Acronym
- UP-LONGCOVID-R
- Status last verified
- May 2025
- First submitted
- 28 Mar 2025
- Last updated
- 22 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Martinez-Borba V, Rodriguez-Marquez AE, Garces-Arilla S, Peris-Baquero O, Navarro-Haro MV, Del Corral-Beamonte E, Osma J. Effectiveness and acceptability of the unified protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19: Study protocol for a randomized controlled trial. PLoS One. 2026 Feb 17;21(2):e0342908. doi: 10.1371/journal.pone.0342908. eCollection 2026.
PubMed 41701690
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.
- ClinicalTrials.gov ID
- NCT06928480
- Acronym / sponsor ID
- UP-LONGCOVID-R / UP-LONGCOVID-RCT
- Keywords
- Long COVID-19, Emotional Disorders, Emotion regulation skills, Unified Protocol, Transdiagnostic, Psychological, Cognitive Behavioral
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Instituto de Investigación Sanitaria AragónUniversity, hospital or other
- Collaborators
- Hospital Universitario Royo Villanova
- Study start
- 1 May 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 15 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain.
In this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, levels of chronic stress will be longitudinally evaluated in the experimental group through accumulated cortisol levels in hair, before and after the application of the UP.
Detailed description
The COVID-19 disease has caused one of the largest pandemics in history, with significant health, social, and economic negative consequences. A significant proportion of the population has not overcome these negative consequences. It has been found that 10-20% of patients with COVID-19 do not recover their previous health status and develop persistent symptoms over time. This condition has been defined by the WHO as post-COVID-19 condition or long COVID-19, characterized by the presence of physical, cognitive, and emotional symptoms that can last for months or even years after the acute COVID-19 infection. Some of the most prevalent symptoms are fatigue, difficulty breathing, and cognitive dysfunction, in addition to significant psychological impairments. Among these, emotional disorders (ED) are the most commonly reported in this population, including anxiety disorders, depressive disorders, and related conditions.
The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is a transdiagnostic Cognitive Behavioral Therapy-based pychological intervention, which has proven to be effective for the treatment of emotional disorders in different populations. The UP is focused on improving emotion regulation skills.
The main objective of this randomized controlled trial is to evaluate the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in 90 adults (45 in the control group and 45 in the experimental group) with long COVID and a comorbid emotional disorder. The researchers hypothesize that the application of the UP will result in a significant reduction in emotional symptoms in the experimental group, compared to the control group. To analyze this results, the evolution of symptoms (i.e., anxiety and depressive symptoms, etc.) will be assessed over time (before and after the intervention, as well as up to 12 months follow-up). Additionally, the acceptability and satisfaction of participants after receiving the UP will be analyzed, and it will be examined whether changes in emotional symptoms are associated with changes in long COVID physical symptoms. Changes in cortisol and cortisona levels will be longitudinally examined in the experimental group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Unified Protocol Psychological Intervention | Experimental | Behavioral: Unified Protocol for the Transdiagnostic Treatment of Emotional DisordersThe 45 participants assigned to this condition will receive the Unified Protocol psychological intervention through 12 sessions. Weekly session will be conducted online (via Google Meet). Each sessions will last 2 hours. |
| Control Group-Waiting list | Other | Other: Treatment as Usual (TAU)The 45 participants assigned to this condition will remain as a control group on a waiting list for the 12 weeks of the program that participants in the experimental group receive. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Residing in Autonomous Community of Aragon (Spain).
- Being at least 18 years old.
- Understanding of Spanish.
- Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection.
- Symptoms of depression (ODSIS≥7) and/or anxiety (OASIS≥8).
Key exclusion criteria (5 listed)
- Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection.
- Actually receiving psychological treatment.
- Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.).
- Active suicidal ideation at the time of the assessment.
- Individuals on psychotropic medication must maintain their dosage throughout the study, unless medically contraindicated.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Unified Protocol for the Transdiagnostic Treatment of Emotional DisordersThis transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7). In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows: * Module 1 (session 1): Setting goals and maintaining motivation. * Module 2 (sessions 2 and 3): Understanding your emotions. * Module 3 (sessions 4 and 5): Mindful Emotions Awareness. * Module 4 (sessions 6 and 7): Flexible thinking. * Module 5 (session 8): Emotional baheviors. * Module 6 (session 9): Facing physical sensations. * Module 7 (sessions 10 and 11): Emotionl exposures. * Module 8 (Session 12): Relapse prevention. | Behavioural | Unified Protocol Psychological Intervention |
| Treatment as Usual (TAU)This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19. After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition. | Other | Control Group-Waiting list |
Primary outcome
General Depression Severity and Interference Scale (ODSIS; Bentley et al., 2014. Validated in Spanish by Osma et al., 2019)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
It assesses the frequency, intensity, severity and interference of depressive symptomatology through 5 items. total scores range from 0 to 20 points, higher scores indicating more severe depressive symptoms.
General Severity and Interference Scale for Anxiety (OASIS; Norman et al., 2006. Validated in Spanish by Osma et al., 2019)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
It consiste of 5 items that assess the frequency, intensity, severity and interference of anxious symptomatology. Total scores range from 0 to 20 points, higher scores represent more severe anxiety symptoms.
12 secondary outcomes
Memory Failures of Everyday, MFE (Sunderland et al., 1983; Montejo et al., 2014)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Multidimensional Inventory for Emotional Disorders (MEDI; Rosellini and Brown, 2019. Validated in Spanish by Osma et al., 2023)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Emotional Regulation Difficulties Scale (DERS; Gratz and Roemer, 2004. Validated in Spanish by Hervás & Jódar, 2008)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
EuroQol (Brooks, 1996. Validated in Spanish by Badia et al., 1999)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Distress Tolerance Scale (DTS; Sandín et al., 2017)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
Perceived Stress Scale (PSS; Remor y Carrobles, 2001)
Time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
An adaptation of Client Satisfaction Questionnaire (CSQ-8) of Larsen et al., 1979)
Time frame: After the treatment is applied (post-assessment; approximately 12 weeks after the intervention starts)
Evaluation questionnaire of the UP modules (Ad hoc)
Time frame: After the treatment is applied (post-assessment; approximately 12 weeks after the intervention starts)
Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005)
Time frame: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Digit Symbol subtest-Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler, 1997)
Time frame: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Digit subtest from Wechsler Adult Intelligence Scale-IV (WAIS-IV; Wechsler, 2008)
Time frame: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Cortisol and cortisona levels
Time frame: Only in the experimental group: Before the treatment; at two points follow up (3 and 12 months after the intervention ended)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2025.
- Derived from this study: PubMed 41701690Martinez-Borba V, Rodriguez-Marquez AE, Garces-Arilla S, Peris-Baquero O, Navarro-Haro MV, Del Corral-Beamonte E, Osma J. Effectiveness and acceptability of the unified protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19: Study protocol for a randomized controlled trial. PLoS One. 2026 Feb 17;21(2):e0342908. doi: 10.1371/journal.pone.0342908. eCollection 2026.
- Individual participant dataSharing planned: Yes
Related trials for Long Covid-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders and Treatment as Usual (TAU) in people with Long Covid-19 and Emotional Disorder, run by Instituto de Investigación Sanitaria Aragón at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jorge Osma Jorge Osma, PhD (+34 978645390, osma@unizar.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
General Depression Severity and Interference Scale (ODSIS; Bentley et al., 2014. Validated in Spanish by Osma et al., 2019) (time frame: Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06928480, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2025.